Personalized treatment of serious infections: From COVID-19 to bacterial sepsis. Humanity is experiencing a devastating pandemic from the new SARS-CoV-2 (COVID-19) coronavirus. The disease is having a catastrophic impact on the conditions of our lives and our society. Since early spring 2020, all members of the Hellenic Sepsis Study Group are united in a huge
Sepsis and precision medicine: The leading position of Greece. The pandemic caused by the new coronavirus SARS-CoV-2 (Covid-19 disease) was the springboard for the emergence of the Greek Sepsis Study Group as a protagonist of international therapeutic developments in the treatment of patients with serious infections. On 16 December 2021, the European Medicines Agency authorized
National Conference of Hellenic Sepsis Study Group The pandemic caused by the new coronavirus SARS-CoV-2 (disease COVID-19) was the springboard for the emergence of the Greek Sepsis Study Group as a protagonist of international therapeutic developments in the treatment of patients with serious infections. After the authorization of the drug anakinra for the treatment of
ImmunoSep: Read more Download the Program 🡇 Abstract book 🡇 Available speakers' presentations (published with their granted permission): Jeremie Poschmann, Nantes University, France Despoina Koulenti, University of Athens, Greece Antoni Torres, University of Barcelona, Spain Antigone Kotsaki, Hellenic Institute for the Study of Sepsis, Greece Frank
Precision Management of Severe Infections and Sepsis: from Translational Research to Clinical Practice Download the Programme ⤵ PROGRAM DETAILS: Hours : 20 hours and 45 minutes REGISTRATION FEE FOR PARTICIPATION: € 140,00 + Vat 24% - Total € 173,60 Includes: Access to 2 days sessions, coffee breaks, congress material.
Download the Programme ⤵
